Zypher Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 25.00 Cr
- Revenue Growth %
- Profit Growth -150.74%
- Ebitda -150.74%
- Net Worth -15.45%
- Total Assets -19.32%
About Zypher Lifesciences
Zypher Lifesciences Private Limited (ZLPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 March 2007 and has a history of 17 years and ten months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹25.00 Cr.
Aditya Bhatia, Anita Bhatia, and Gunjan Bhatia serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U29297DL2007PTC160681
- Company No.
160681
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Mar 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Zypher Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aditya Bhatia  | Director | 19-Mar-2007 | Current |
| Anita Bhatia | Director | 17-Nov-2020 | Current |
| Gunjan Bhatia | Director | 17-Nov-2020 | Current |
Financial Performance of Zypher Lifesciences.
Zypher Lifesciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 150.74% decrease in profit. The company's net worth observed a substantial decline by a decrease of 15.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zypher Lifesciences?
In 2020, Zypher Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ruxall Vita Private LimitedAditya Bhatia, Anita Bhatia and 1 more are mutual person
- Medcell Pharma Private Limited
Aditya Bhatia, Anita Bhatia and 1 more are mutual person
Charges (Loans)
₹250.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 25.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Feb 2024 | Hdfc Bank Limited | ₹25.00 Cr | Open |
How Many Employees Work at Zypher Lifesciences?
Unlock and access historical data on people associated with Zypher Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zypher Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zypher Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
